FEMY News and Press, Femasys Inc. From 11/30/23

2023-11-30 17:40:37 ET More on Femasys Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner Femasys regains Nasdaq compliance Financial information for Femasys For further details see: Femasys filed to sell 18.11M shares of common st...

2023-11-30 08:47:02 ET More on Femasys Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner Femasys regains Nasdaq compliance For further details see: Femasys appoints Liu as its chief medical officer

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic...

2023-11-28 08:40:23 ET Summary Femasys is a medical device company that offers a suite of minimally invasive reproductive health products for women. The company recently received clearance for its FemaSeed product and plans to launch it in early 2024. Femasys is also developin...

- Topline results from FemaSeed ® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 - ATLANTA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women wor...

New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys...

- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys’ infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasy...

2023-11-14 08:57:41 ET More on Femasys Femasys regains Nasdaq compliance Seeking Alpha’s Quant Rating on Femasys Historical earnings data for Femasys Financial information for Femasys For further details see: Femasys GAAP EPS of -$0.26, rev...

- 510(k) product clearance gained for lead product, FemaSeed potentially allowing sooner-than-expected product commercialization - - Patient enrollment has commenced in landmark, pivotal FINALE trial for lead product candidate, FemBloc ® , with academic sites enrolling ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...